洛匹那韦/利托那韦抗新型冠状病毒治疗的可行性及临床评价

目的 评价洛匹那韦/利托那韦抗新型冠状病毒治疗的应用可行性、临床效果及安全性。方法 最近在中国暴发的新型冠状病毒肺炎(简称新冠肺炎)疫情,目前尚无针对性强的抗病毒药物,临床尝试"老药新用",以2003年严重急性呼吸综合征(SARS)和2012年中东呼吸综合征(MERS)疫情中使用的一线抗病毒药物洛匹那韦/利托那韦来抗新型冠状病毒治疗。分析该药的抗病毒药理作用、临床应用可行性,评价其临床应用效果和安全性。结果 洛匹那韦/利托那韦治疗冠状病毒感染性疾病有一定临床基础,可重建宿主的免疫功能,抗新型冠状病毒有一定疗效,但有较高的耐药屏障。结论 洛匹那韦/利托那韦用于抗新型冠状病毒治疗可行,临床疗效较好,但应用期间要加强药学监护,尤其是合并用药和特殊人群应用时,注重安全、合理用药。

Feasibility and Clinical Evaluation of Lopinavir/Ritonavir in the Treatment of the Severe Acute Respiratory Syndrome-Coronavirus-2

Objective To evaluate the feasibility,clinical efficacy and safety of lopinavir/ritonavir in the treatment of the severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2).Methods The clinical trial of″new use of old drugs″method was carried out while there were no highly targeted antiviral drugs for the outbreak of the coronavirus disease 2019(COVID-19)epidemic in China,lopinavir/ritonavir,as the first-line antiviral drugs used in the severe acute respiratory syndrome(SARS)epidemic in 2003 and the Middle East respiratory syndrome(MERS)epidemic in 2012,has been used in the treatment of SARS-CoV-2.The antiviral pharmacological effect and clinical application feasibility of lopinavir/ritonavir were analyzed,and its clinical efficacy and safety were evaluated.Results Lopinavir/ritonavir has a certain clinical basis in the treatment of coronavirus infectious diseases,it can reconstruct the immune function of the host and has a certain effect in the treatment of the SARS-CoV-2,but it has a high resistance barrier.Conclusion Lopinavir/ritonavir is feasible and effective in the treatment of the SARS-CoV-2.But during the treatment period,pharmaceutical care should be strengthened,especially when combined with other drugs and used in special groups,we should pay attention to the safe and rational use of drugs.